Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Blood (2023) 142 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2023-186997

Published: 2023

Journal Articles

Clinical Characteristics and Overall Survival Among Acute Myeloid Leukemia (AML) Patients with TP53 Gene Mutation (TP53m) or Chromosome 17p Deletion (17p del)

Naval Daver, Shahed Iqbal, Julie Huang, Camille Renard, Joyce Lin, Harry Pan, Guan Xing, Yang Pan, Giri Ramsingh

Blood (2022) 140 (Supplement 1): 1445–1446.

https://doi.org/10.1182/blood-2022-170298

Published: 2022

Journal Articles

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53 -Mutant Acute Myeloid Leukemia

Naval Daver, Paresh Vyas, Mark Chao, Guan Xing, Camille Renard, Giri Ramsingh, David A. Sallman, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 3426.

https://doi.org/10.1182/blood-2021-145208

Published: 2021

Journal Articles

A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia

Paresh Vyas, Naval Daver, Mark Chao, Guan Xing, Camille Renard, Giri Ramsingh, Andrew H. Wei, David A. Sallman

Blood (2021) 138 (Supplement 1): 3424.

https://doi.org/10.1182/blood-2021-145584

Published: 2021